Receive ADMET case studies from Genentech, Roche, AstraZeneca, GSK, UCB, Janssen, Novartis and more

SOUTHWARK, U.K. - June 8, 2015 - PRLog -- SMi’s 10th annual ADMET conference will feature case studies from Genentech, Roche, AstraZeneca, GSK, UCB, Janssen, Novartis, Johnson & Johnson and Vertex Pharmaceuticals among others, who will be providing insight of the latest technologies being utilised, metabolomics, predictive toxicology and ADME/Tox screening at early stages of drug discovery where the development process has become even more crucial. This year’s two-day conference agenda will build on the success of the 2014 event by addressing:
• In vitro models and technologies for detecting cardiotoxicity
• Performance analysis of different in vitro models to detect human hepatotoxic drugs
• Human stem cell derived cardiomyocytes
• Regulatory DDI guidance for drug transporters - an overview review of current FDA, EMA and JMHLW (Japan) guidance for industry
• Mitigating errors in early human dose predictions and setting the criteria for ADME end points

Attend SMi's 10th annual ADMET conference to:
• Receive 17 case studies from speakers representing both the pharma and biotech industries addressing the development of human cellular models and state-of-the-art in vitro used to assess toxicity, plus over 3 hours of networking sessions discussing and analysing the latest novel technologies being used in the field of Predictive Toxicology and ADME/Tox
• Network with a global audience of leading scientists and key decision makers in the ADMET arena. Confirmed attendees include: Boehringer Ingelheim, Astex Pharmaceuticals, Orion Corporation, Orion Pharma, Xenotech LLC, University Of Basel, Polyphor Ltd, plus many more

Key Speakers include:
• Araz Raoof, Head Scientific Affairs & Analysis, Janssen Pharmaceutica
• Professor Ian D. Wilson, Professor of Drug Metabolism, Imperial College London
• Laurent Salphati, Senior Scientist, Genentech
• Thierry Lave, Global Head DMPK & Tox Project Leaders and Modelling & Simulation, F. Hoffmann-La Roche
• Peter Clements, Director of Pathology, GSK
• Stephen Fowler, Group Leader, In Vitro ADME, F. Hoffmann-La Roche
• Franck Atienzar, Associate Director In Silico In Vitro Toxicology, UCB BioPharma SPRL
• Peter Hoffmann, Executive Director, Pre-Clinical Safety, Novartis Institutes for BioMedical Research
• Mario Monshouwer, Senior Director Drug Metabolism Pharmacokinetics & Bioanalysis, Johnson & Johnson

To view the full speaker line-up and conference programme, visit http://www.smi-online.co.uk/2015admet18.asp